Email to a friend
Print this page
 
July 16, 2010
Biolux Research Announces Financing For Continued Development of its Light Accelerated Orthodontics Product

VANCOUVER, B.C., CANADA - July 16, 2010
-
Biolux Research Ltd. is pleased to announce that it has recently raised over CAD $1MM as part of a new equity offering of common shares. The funds were raised through a convertible debt mechanism offered to existing shareholders and optionholders of the company in advance of a planned further offering to the broader investment community in the near future.

[click here to download PDF]
June 24, 2010
Biolux Research Announces Filing of Patent Application for Regulation of Orthodontic Tooth Movement

VANCOUVER, B.C., CANADA - June 24, 2010
-
Biolux Research Ltd. is pleased to announce the filing of a second patent application for a method and apparatus for accelerating and regulating orthodontic tooth movement with light treatment technology. The company filed the application through the Patent Cooperation Treaty process, which will allow for expansion of patent protection to over 200 countries, including all major markets of the world.

[click here to download PDF]
June 10, 2010
Biolux Research Announces Presentation of Accelerated Orthodontic Study Results at International Association for Dental Research General Session 2010

VANCOUVER, B.C., CANADA - June 10, 2010
-
Biolux Research Ltd. is pleased to announce that important results from our accelerated orthodontics research program will be presented at the upcoming International Association for Dental Research (IADR) General Session in Barcelona, Spain, July 14-17, 2010. The IADR is the pre-eminent research organization in the world of dentistry, with a mission to advance research and increase knowledge for the improvement of oral health worldwide, to support and represent the oral health research community, and to facilitate the communication and application of research findings. This year’s meeting will be highly attended by more than 5000 members from all corners of the globe.

[click here to download PDF]
May 10, 2010
Biolux Research announces Presentation of the Osseopulse™ at Ontario Dental Association Annual Spring Meeting 2010

VANCOUVER, B.C., CANADA - May 10, 2010
-
Biolux Research Ltd. is pleased to announce that the OsseoPulse? Bone Regeneration System has been selected for presentation in the New Products Forum at the Ontario Dental Association Annual Spring Meeting in Toronto May 13-15, 2010. The presentation will highlight the clinical treatment opportunities with the OsseoPulse™, an innovative light treatment product that stimulates bone regeneration, allowing the dentist to dramatically reduce time to load dental implants and to treat challenging cases with increased confidence. The forum is a classroom setting with interactive discussion, and the presentation is supported by Citagenix Inc, distributor of the OsseoPulse™ in Canada.

[click here to download PDF]
April 26, 2010
Biolux Research announces Design Award for the Osseopulse™ Bone Regeneration System for Implantology

VANCOUVER, B.C., CANADA - April 26, 2010
-
Biolux Research Ltd. is pleased to announce that it has received the prestigious red dot product design award for the OsseoPulse™ Bone Regeneration System, in recognition of the innovative design of the medical product.

[click here to download PDF]
November 5, 2009
Biolux Research announces financing and investigational testing authorization for the development of a light accelerated orthodontics product

VANCOUVER, B.C., CANADA - November 5, 2009
-
Biolux Research Ltd. is pleased to announce that it has issued $860,000 in new shares as part of a new equity offering of common shares.

The offering included a debt conversion vehicle to convert shareholder loans, in which the principle shareholders of the company converted the majority of promissory notes into new shares. The majority of the offering was purchased by Elac Venture Corporation, a private equity investing firm based in Hong Kong. The remainder of the offering was purchased by existing shareholders and individual investors.

[click here to download PDF]
August 13, 2009
Biolux Research announces support from the National Research Council of Canada Industrial Research Assistance Program for the development of light accelerated orthodontics product.

VANCOUVER, B.C., CANADA - Aug. 13, 2009
-
Biolux Research Ltd. is pleased to announce that it has received a non-repayable financial contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to help accelerate the development and commercialization of a new light treatment device for orthodontics. The new product will be designed to significantly accelerate tooth movement during orthodontic treatment, and thus radically reduce treatment times and improve the experience for patients.

NRC-IRAP will contribute approximately CAD $205,000 over the next 18 months to support the research and prototyping of the device, to clinically test and validate the effectiveness of the technology, and to develop a high quality, manufacturable product. In addition to the contribution, NRC-IRAP will provide both technical and business oriented advisory services.

[click here to download PDF]
June 26, 2009
Biolux Research Announces OsseoPulse™ Production Milestone and Expanding Distribution.

VANCOUVER, B.C., CANADA - Jun. 26, 2009
-
Biolux Research Ltd. is pleased to announce today that we have achieved a production milestone for our OsseoPulse™ Bone Regeneration System, and have expanded our product distribution into additional markets.

Since launching the OsseoPulse™ in Canada in Oct. 2008, we have received regulatory clearance in Canada, Korea, Israel, and Europe. Achieving CE Mark is a significant achievement as it provides direct regulatory approval for approximately 20 European countries.

[click here to download PDF]
June 15, 2009
Biolux Research Announces Filing of Patent Application for Light Accelerated Orthodontics.

VANCOUVER, B.C., CANADA - Jun. 15, 2009
-
Biolux Research Ltd. is pleased to announce today the filing of a patent application for a method and apparatus for accelerating orthodontics with light treatment technology.

Orthodontics is the dentistry specialty of moving teeth within the jaw to provide better alignment and other benefits, and is a very common dental procedure. There are approximately 10,000 orthodontists in the US and Canada, with approximately 2 million patients undergoing orthodontic treatment in an average year. Orthodontic treatment is traditionally achieved with appliances (braces) that provide physical force to the teeth and move the roots through the bone. Typical orthodontic treatments range from 12 to 36 months, due to the natural limitations of bone resorption and regeneration processes, and consist of frequent visits to the orthodontist for adjustments and tightening. Reducing overall treatment time can provide a much better experience for the patient, including less social stigma, discomfort, and change of diet, while accelerating the process presents new opportunities to the orthodontist to provide different and better care.

[click here to download PDF]
March 18, 2009
Biolux Research Announces European Launch of the OsseoPulse? Bone Regeneration System.

VANCOUVER, B.C., CANADA - Mar. 18, 2009
- Biolux Research Ltd. is pleased to announce today that it will be launching the OsseoPulse? Bone Regeneration System at the 33rd International Dental Show from Mar. 24 - 29. http://english.ids-cologne.de/ IDS 2009 in Cologne, Germany is the world's leading trade show and sector meeting place for decision-makers from dental practices, dental labs, the specialist dental trade, the dental industry and from research and development. More than 100,000 visitors gather information on new products and innovations from some 1,750 exhibitors from 55 countries.

Launch of the OsseoPulse™ in Europe builds on recent milestones of achieving both ISO 13485 certification and CE Mark regulatory approval for the product. The CE Mark allows Biolux to market the device directly to the 27 countries within the European Union plus the additional 4 countries that recognize the CE Mark. The dental implant market in Europe represents approximately 40% of the worldwide implant market, and is thus a significant market for Biolux and the OsseoPulse™.

[click here to download PDF]
February 5, 2009
Biolux Research Announces ISO 13485 Quality System Certification and CE Mark Regulatory Approval of the OsseoPulse? Bone Regeneration System.

VANCOUVER, B.C., CANADA - Feb. 5, 2009
- Biolux Research Ltd. is pleased to announce today two news items that will further enhance the commercialization of its OsseoPulse? Bone Regeneration System.


The company has successfully completed its ISO 13485 certification audit and has been awarded a final certificate. ISO 13485 is a worldwide-recognized medical device quality system standard, and certification to this standard is a requirement for any medical device company to develop, manufacture, and market products in Europe, Canada, and other markets. The Biolux quality system was audited by BSI Management Systems America Inc., one of the foremost auditing bodies in the world.

[click here to download PDF]
December 1, 2008
Biolux Research Announces Commercial Launch of the OsseoPulse? Bone Regeneration System in Korea.

VANCOUVER, B.C., CANADA – Dec. 1, 2008 – Biolux Research Ltd. is pleased to announce today that it has launched the OsseoPulse? Bone Regeneration System in South Korea. The product is now available for sale exclusively through DIO Implant Inc., a division of publicly-traded Dong Seo Inc, under the distribution agreement signed earlier in 2008. The product has been approved by the Korean FDA as a Class II device, and product has been shipped to DIO to begin marketing and sales of the OsseoPulse? to luminaries and opinion leaders.


[click here to download PDF]
October 31, 2008
Biolux Research Announces Launch of the OsseoPulse™ Bone Regeneration System in Canada.

VANCOUVER, B.C., CANADA – Oct. 31, 2008 – Biolux Research Ltd. is pleased to announce today that it has launched the OsseoPulse? Bone Regeneration System in Canada. The product is now available for sale through Citagenix Inc., our exclusive distribution partner. The product has been approved by Health Canada as a class II medical device, and received a medical device license earlier in 2008. Production quality has been proven, sales training has taken place, and product has been shipped to Citagenix to begin marketing and sales.


[click here to download PDF]
August 20, 2008
Biolux Research Announces Appointment of Dr. Cameron Clokie as Chair of Scientific Advisory Board.

VANCOUVER, B.C., CANADA ? August 20, 2008 ? Biolux Research Ltd. Is very pleased to announce that it has appointed Dr. Cameron Clokie, DDS, OMFS, PhD, as Chair of its Scientific Advisory Board (SAB). Dr. Clokie is renowned in the field of implantology, and was part of the pioneering group to develop the clinical field in Canada decades ago. For the past ten years Dr. Clokie served as Head of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Toronto, and is currently a partner at very successful private practice in Toronto. Dr. Clokie has also successfully commercialized numerous dental products in the tissue regeneration space.


[click here to download PDF]
July 24, 2008
Biolux Research Announces Agreement with Citagenix for Exclusive Distribution of the OsseoPulse? Bone Regeneration System in Canada.

VANCOUVER, B.C., CANADA ? July 24, 2008 ? Biolux Research Ltd. announced today that it has signed a new distribution agreement with Citagenix Inc. to commercialize the OsseoPulse? Bone Regeneration System in Canada. The agreement provides exclusivity and a long term commitment necessary to introduce the new product to the Canadian dental market.


[click here to download PDF]
May 7, 2008
Biolux Research Announces Health Canada Regulatory Approval for its OsseoPulse™
Bone Regeneration System.


VANCOUVER, B.C., CANADA - May 7, 2008 – Biolux Research Ltd. announced today that it has received approval from Health Canada to market the OsseoPulse™ Bone Regeneration System in Canada. The OsseoPulse™ is classified by Health Canada as a Class II medical device, and received a Medical Device Licence for the system and its components. The licence was applied for in partnership with StarFish Medical of Victoria, BC.


[click here to download PDF]
April 4, 2008
Biolux Research Announces Appointment of President and CEO for Commercialization
of its OsseoPulse™ Bone Regeneration System.


VANCOUVER, B.C., CANADA. - April 4, 2008 Biolux Research Ltd. announced today that it has appointed medical device industry veteran Kevin Strange as President and CEO. Mr. Strange’s primary responsibilities will be to lead the commercialization of the unique OsseoPulse™ Bone Regeneration System for dentistry, including product launch into Canada, the US, and Europe, as well as executing work in Korea with our strategic partner DIO Implant, subsidiary of a publicly listed medical device manufacturer and distributor. Dr. Peter Brawn, Chairman and Founder of Biolux, will continue the key roles of clinical and scientific visionary and early product research and development.

[click here to download PDF]
 
 
September 22, 2007
Biolux Research Announces Memorandum of Understanding with Dong Seo Inc. of South Korea
for its OsseoPulse™ Bone Regeneration System.


VANCOUVER, B.C., CANADA. - September 18, 2007 Biolux Research Ltd. announced today that it has signed a Memorandum of Understanding (MOU) with DIO Implant, a wholly owned subsidiary of Dong Seo Inc, which in turn is a KOSDAQ stock exchange listed company and one of Korea’s leading dental implant manufacturers. The MOU is for the purpose of product evaluation, marketing and completion of an exclusive distribution agreement for the OsseoPulse™ dental bone regeneration system in South Korea.

[click here to download PDF]
 
 
Copyright © 2004 - Biolux Research Ltd. All rights reserved. Terms of UsePrivacy PolicyContact Us